Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment

PURPOSE: To report on the management and effectiveness of treating patients with stage I Neurotrophic Keratitis using an 8-week course of topical recombinant human nerve growth factor (rhNGF, cenegermin). OBSERVATIONS: In this retrospective case series, punctate epithelial erosions (PEE), best corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Epitropoulos, Alice T., Weiss, Jamie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350864/
https://www.ncbi.nlm.nih.gov/pubmed/35938145
http://dx.doi.org/10.1016/j.ajoc.2022.101649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350864/
https://www.ncbi.nlm.nih.gov/pubmed/35938145
http://dx.doi.org/10.1016/j.ajoc.2022.101649

Ejemplares similares